Aurealis Therapeutics Stock

Aurealis Therapeutics is a swiss-finnish private biopharmaceutical company

Sign up today and learn more about Aurealis Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Aurealis Therapeutics Stock

They exist to develop curative solutions that achieve total and faster healing for non-healing wounds and other complex inflammatory diseases with their four-in-one biologic drug, AUP-16. Their goal is to create solid Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in other inflammatory diseases by end of 2022, and to engage with strategic partners to ensure that this game changing technology benefits millions of patients.

Funding History

March 2023$10.0M

Management

CEO

Juha Yrjänheikki

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo